Zhihu Inc. (ZH)
NYSE: ZH · Real-Time Price · USD
4.160
-0.070 (-1.65%)
Aug 1, 2025, 4:00 PM - Market closed
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Ligand Pharmaceuticals stock has a target of 4.70, which predicts a 12.98% increase from the current stock price of 4.16.
Price Target: $4.70 (+12.98%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 29, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for Ligand Pharmaceuticals is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $5.4 → $4.7 | Strong Buy | Maintains | $5.4 → $4.7 | +12.98% | Nov 29, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $8.4 → $5.4 | Strong Buy | Maintains | $8.4 → $5.4 | +29.81% | Jun 13, 2024 |
| Jefferies | Jefferies | Strong Buy Maintains $11 → $6.6 | Strong Buy | Maintains | $11 → $6.6 | +58.65% | Mar 11, 2024 |
| CLSA | CLSA | Buy Initiates $9 | Buy | Initiates | $9 | +116.35% | Dec 14, 2022 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $14 → $12 | Hold | Maintains | $14 → $12 | +188.46% | Dec 1, 2022 |
Financial Forecast
Revenue This Year
3.10B
from 3.60B
Decreased by -13.95%
Revenue Next Year
3.33B
from 3.10B
Increased by 7.46%
EPS This Year
-1.83
from -1.89
EPS Next Year
0.74
from -1.83
Financial currency is CNY. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 3.2B | 3.5B | 3.5B | |
| Avg | 3.1B | 3.3B | 3.4B | |
| Low | 2.9B | 3.2B | 3.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -10.5% | 11.9% | 5.9% | |
| Avg | -13.9% | 7.5% | 2.8% | |
| Low | -18.1% | 2.1% | -1.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -1.88 | 0.98 | 3.21 | |
| Avg | -1.83 | 0.74 | 3.12 | |
| Low | -1.75 | 0.50 | 3.00 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | 336.0% | |
| Avg | - | - | 323.5% | |
| Low | - | - | 306.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.